Latest News

Nvidia Is One Less Brick On The Wall Of Worry, For Now
Nvidia beat expectations and raised 2028 revenue growth guidance to 70%, reinforcing AI sector strength despite supply constraints. AI accelerator demand remains robust, but questions persist about NV

Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance
Agilent Technologies is upgraded to Buy after a strong Q3 2026, with revenue up 8% and EPS up 18% YoY. All three segments posted robust growth, notably Life Sciences and Diagnostics, which saw operati

Teradyne: AI Is Turning Test Into A Structural Growth Market
Teradyne is well-positioned to benefit from rising AI-driven test complexity across compute, memory, and photonics, supporting a BUY rating. TER's diversified test platforms and early qualification in

Ravi Kumar S Recognized on TIME100 AI List for Shaping the Future of Enterprise AI
Cognizant CEO honored for helping redefine enterprise AI transformation through workforce reinvention and next-generation operating models TEANECK, N.J., Aug. 27, 2026 /PRNewswire/ -- Cognizant (Nasda

Kansas City Fed's Schmid says inflation 'stubborn' and 'sticky,' policy rate not restrictive
Kansas City Fed President Jeffrey Schmid said Thursday that inflation has been "stubborn" and "sticky" though he did not commit to supporting an interest rate hike. However, he said he doesn't see the

Class Action Lawsuit Filed Against Photronics (PLAB): What Investors Need to Know by September 4 Lead Plaintiff Deadline
Hagens Berman Urges Investors with Significant Losses to Contact the Firm KEY DATES AND FIGURES Class Period: Dec. 10, 2025 - May 27, 2026 Lead Plaintiff Deadline: Sept. 4, 2026 Case Page: www.hbsslaw

HDB ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages HDFC Bank Limited (HDB) Investors to Contact its Legal Team Regarding Securities Fraud Class Action Lawsuit
San Francisco, California--(Newsfile Corp. - August 27, 2026) - Hagens Berman, a national law firm noted for its preeminent work in securities class action litigation, notifies investors in HDFC Bank

PRCT INVESTOR ALERT: PROCEPT BioRobotics Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
San Francisco, California--(Newsfile Corp. - August 27, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has be

Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman
San Francisco, California--(Newsfile Corp. - August 27, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has

CAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
San Francisco, California--(Newsfile Corp. - August 27, 2026) - National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Followin

Strattec Security: Auto Industry Prospects Will Likely Dominate (Downgrade)
Strattec Security Corporation faces significant macro headwinds from persistent high oil prices and a weakening auto industry outlook. Auto industry forecasts are deteriorating, and management's cost-

Why The Cisco Deal Only Solves Half Of Super Micro's Problem
This article was written by Doug Nathman, with research by his team at Trefis.

Siemens Energy: Gas, Grid, And Gamesa Are Finally Pulling Together
I'm reiterating Siemens Energy AG is reiterated as a Strong Buy with a new $220 price target after robust Q3 2026 results. SMEGF's backlog surged to €162 billion, quarterly revenue rose 19% y/y, and g

Accelleron Industries AG (ACLLY) Q2 2026 Earnings Call Transcript
Accelleron Industries AG (ACLLY) Q2 2026 Earnings Call Transcript

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal

Okta's Buy Thesis Holds, But The Margin For Error Is Smaller
Okta remains a Buy, supported by steady revenue growth, expanding enterprise accounts, and improving margins. OKTA's FY27 guidance targets 10-11% revenue growth, 26% non-GAAP operating margin, and 28-

MOAT: Software Stocks Powering Recent Gains For This $12.5 Billion Wide Moat ETF
VanEck Morningstar Wide Moat ETF delivered strong recent outperformance, gaining 10.23% versus peers since my last review, driven by deeply discounted valuations and overweighted software stocks. MOAT

AT&T: From Contained Downside To Unpriced Upside
AT&T is upgraded to Strong Buy, reflecting improved FCF guidance, pricing power, and earnings acceleration. T now guides FCF to $18B for 2026, with coverage and dividend growth prospects improving an

Celestica Could Benefit Massively From Jalapeño Chip Ramps (Rating Upgrade)
Celestica delivered 62% revenue growth and 83% adjusted EPS growth, supported by strong AI infrastructure demand and expanding operating leverage. The Communications and Cloud Solutions segment genera

Lion Rock Extends Tin and Tantalum Mineralization at Volney as Phase 2 Drill Planning Begins
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2026) - Lion Rock Resources Inc. (TSXV: ROAR) (OTCQB: LRRIF) (FSE: KGB) ("Lion Rock" or the "Company") has completed a property-wide surface e